Citations

Clear

439 citation(s) found for "Stone, M".

Big Data in Neurosurgery: A Guideline on Data Structures, Machine Learning Models, and Ethical Considerations
Singh, Rohin , Kassis, George, Sbaih, Omar, Li, Herman , Lawton, Michael T. , Gottfried, Oren N., Bydon, Mohamad , Stone, Jonathan, Singh, Rohin , Sbaih, Omar I. , Shahrestani, Shane

Mayo Clinic

Operative Neurosurgery | August 25, 2025 | Volume: 30 | Issue: 6 | Pages: 819-826

10.1227/ons.0000000000001751 | PMID 40853158 Get It

Artificial intelligence (AI) is reshaping neurosurgery, offering unprecedented opportunities to enhance diagnostics, personalize treatment, and predict outcomes. At the heart of this transformation is the ability to effectively harness big data (BD) within the electronic medical record. Understanding these data structures is essential for making sense of the vast volumes of information generated in modern neurosurgical practice. Equally important are the machine learning (ML) models driving these advancements. From supervised learning and convolutional neural networks to generative AI, these tools are already making a mark in areas such as brain tumor segmentation and spine surgery outcome predictions. Their versatility highlights the potential of ML to complement clinical expertise and streamline decision-making in neurosurgery. However, adopting BD and ML also brings ethical challenges that cannot be ignored. Bias in algorithms threatens to reinforce health disparities, whereas concerns about data privacy demand vigilance in handling sensitive patient information. In addition, the question of liability looms large as ML increasingly influences clinical decisions. The aim of the study was to provide a roadmap for neurosurgeons navigating the evolving intersection of BD, ML, and ethical responsibility in the AI era.
Genetic and Clinical Characterization of a Large Cohort with Suspected Monogenic Stone Disease
Cogal, Andrea G. , Ali, Ahmed E. , Arnous, Muhammad G. , Zhou, Le‐Ting , Arroyo, Jennifer, Seide, Barbara M., Reynolds, Laura M. , Kennedy, Gabrielle N. , Milliner, Dawn S. , Sas, David J. , Harris, Peter C. , Cheungpasitporn, Wisit , Tan-Arroyo, Jennifer , Alhadi, Abdulmueti , Arroyo, Jennifer , Seide, Barbara M , Rossler, Kalina J , Reynolds, Laura M , Kennedy, Gabrielle N , Elbarougy, Doaa E , Goldfarb, David S , Milliner, Dawn , Lieske, John C , Harris, Peter C , Cheungpasitporn, Wisit , Alhadi, Abdulmueti , Elbarougy, Doaa E. , Goldfarb, David S. , Lieske, John C.

Mayo Clinic

Clinical Journal of the American Society of Nephrology | August 12, 2025 | Volume: 20 | Issue: 12 | Pages: 1670-1682

10.2215/cjn.0000000817 | PMID 40794449 Get It

Key Points Genetic testing of individuals suspected of monogenic urinary stone disease resolved 34% of families with 22 different genes detected. Resolved individuals had a lower baseline and last visit eGFR and earlier age of stone presentation than the unresolved group. Specific phenotypes and younger diagnostic age were associated with a monogenic cause, allowing refinement of future screenings. Background Urinary stone disease with a clear genetic cause, monogenic stone disease (MSD), is increasingly recognized as a significant proportion of the total population. When MSD is suspected, genetic testing provides a firm diagnosis that can alter management and treatment. Here, we present testing results from a large cohort with suspected MSD. Methods Patients with features suggestive of MSD (early onset, family history, frequent stones, nephrocalcinosis [NC], and/or CKD) were recruited by the Rare Kidney Stone Consortium and genotyped for up to 160 known or candidate MSD genes via a targeted massively parallel sequencing panel. We compared clinical and biochemical features between genetically resolved MSD and unresolved individuals. Results Of 426 families (657 patients) enrolled, 145 (34%) were resolved with identified disease associated variants in 22 known MSD genes. Ninety-nine families were biallelic, 37 monoallelic, and two digenic. An additional 21 of the 231 screened family members were resolved. Genes identified in ten or more families include the following: AGXT , HOGA1 , SLC34A3 , CYP24A1 , SLC3A1 , and CLCN5 . Compared with the unresolved group, MSD probands had a lower baseline and last visit eGFR, earlier age of stone presentation, and more stone events and procedures/year of life. The resolve rate was higher in those <16 years, and NC was seen earlier in the MSD group. Overall, NC was a risk factor for lower eGFR. Among the specific disorders, patients with primary hyperoxaluria had the earliest age of stone and NC diagnosis, and as expected, the highest urinary oxalate level. Conclusions Our study emphasizes the value of selecting patients enriched for factors associated with MSD, and comprehensive genetic testing to achieve a high yield of genetic diagnoses. Significant clinical and biochemical characteristics of patients with MSD were defined. A definitive MSD diagnosis facilitates individualized management and strategies to delay disease progression in probands and affected family members.
Kidney Stone Events and ESKD Incidence in Patients with Enteric Hyperoxaluria from Diverse Enteric Etiologies
Tatton, Ryan W. , O'Neill, Stephen R. , Jordan, Deondre , Vaughan, Lisa E. , Lieske, John C. , Keddis, Mira T. , Lieske, John C , Vaughan, Lisa

Mayo Clinic

Kidney360 | August 11, 2025 | Volume: 7 | Issue: 1 | Pages: 164-176

10.34067/kid.0000000908 | PMID 40788690 Get It

Key Points Significant heterogeneity in patient characteristics, urine metabolic studies, and kidney outcomes exist among enteric hyperoxaluria patients from diverse etiologies. Structurally induced malabsorption and exocrine pancreatic insufficiency have the highest kidney stone event rates. Patients with structurally induced malabsorption have up to 18% ESKD incidence at 5 years. Background Enteric hyperoxaluria (EH) is a risk factor for calcium oxalate nephrolithiasis and kidney disease. The study compares patient characteristics and urine metabolic profiles at the time of EH diagnosis and kidney stones and ESKD events during follow-up in a cohort with diverse causes of EH. Methods Adult patients with newly documented elevated urinary oxalate excretion >40 mg/24 h between January 1, 2010, and October 10, 2023, and a known enteric diagnosis including inflammatory bowel disease, exocrine pancreatic insufficiency (EPI), celiac disease, structural intestinal malabsorption (SIM), or malabsorptive bariatric surgery (Bariatric) were identified. Event rates and cumulative incidence of kidney stones and ESKD were assessed. Results Among 814 identified patients, the most common enteric etiology was Bariatric ( n =524, 64%). Patients with ulcerative colitis had the highest prevalence of kidney stones at EH diagnosis (93.6%) compared with other enteric etiologies ( P = 0.002). Patients with SIM had the highest urinary oxalate, lower urinary citrate, and volume, compared with other enteric etiologies ( P < 0.05). Calcium oxalate supersaturation was similar among the enteric groups ( P = 0.67). Median stone event rate for the overall cohort was 0.70 stone events/year during a mean (SD) follow-up of 5.0 (3.9) years. The SIM and EPI groups experienced the highest stone events (median [IQR] 1.24 [0.28–2.40] and 1.20 [0.41–1.99] events/year, respectively) while the Bariatric group had the lowest event rates (median [IQR] 0.45 [0.00–1.66 events/year]; P < 0.001). The SIM group had the highest ESKD incidence (17.8% 5 years postdiagnosis; log-rank test P < 0.001). Conclusions We describe a large EH cohort from diverse enteric etiologies. Significant heterogeneity exists in patient characteristics, urine metabolic risk factors, and adverse kidney outcomes. Patients with SIM and EPI experienced the highest kidney stone events and patients with SIM had the highest ESKD incidence. This study highlights the urgent need for more granular information regarding the natural history and risk factors for kidney complications for patients with EH to support interventional trials to improve outcomes.
Migraine and functional neurological disorder (FND)—a review of comorbidity and potential overlap
Stone, Jon , Coebergh, Jan , Khoja, Lujain , Butler, Matthew , Nicholson, Timothy R. , Dodick, David W. , Dodick, David W

Mayo Clinic

Brain Communications | August 1, 2025 | Volume: 7 | Issue: 4 | Pages: No page available

10.1093/braincomms/fcaf288 | PMID 40799284 Get It

Abstract Migraine and functional neurological disorder (FND) are two of the most common conditions in neurological practice. It is assumed that the two conditions have distinct underlying mechanisms. However, it can be clinically challenging to disentangle their relative contributions to a patient's symptoms. In addition, apart from the relationship between persistent postural perceptual dizziness (PPPD) and migraine, the frequency of co-occurrence has not been characterized in detail. Contemporary conceptualizations of FND have driven a re-evaluation of its relationship to other neurological disorders, including migraine. We carried out a narrative review of the literature examining the co-occurrence of migraine and FND. We also explored their comorbidities, aetiological risk factors and mechanisms, focusing especially on areas of potential overlap. Our review suggests increased frequency of migraine in people with functional seizures compared to epilepsy, but data from people with functional motor symptoms is mixed. Robust epidemiological studies evaluating the frequency of FND in migraine are lacking. Similar to other neurological disorders, migraine is an established trigger of FND. Female gender, adverse childhood experiences and comorbid psychiatric and functional disorders, such as irritable bowel syndrome and fibromyalgia, are more common in both conditions than in controls, but perhaps more so in FND. Mechanistic research in both conditions highlights converging frameworks of dysregulated allostatic/stress responses in the context of predictive processing models of the brain. This has implications for pharmaceutical and rehabilitation treatments. The relationship between migraine and FND is poorly studied. An overview of their overlap offers a model of non-dualistic thinking within a clinical neuroscience framework for future studies.
Treatment Times and In-Hospital Mortality Among Patients with ST-Elevation Myocardial Infarction Throughout the Waves of the COVID-19 Pandemic: Lessons Learned
Zègre‐Hemsey, Jessica K. , Goyal, Abhinav , Poudel, Ram , Thomas, Kathie , Ali, Murtuza J., Best, Patricia J.M. , Bieniarz, Mark, Fonarow, Gregg C. , French, William J. , Henry, Timothy D. , Hong, Haoyun, Jollis, James G. , Redlener, Michael , Spier, Travis, Stone, Harper, Wahab, Feras, Wang, Lanjing , Jacobs, Alice K. , Granger, Christopher B.

Mayo Clinic

COVID | July 25, 2025 | Volume: 5 | Issue: 8 | Pages: 114

10.3390/covid5080114 Get It

Previous studies about the COVID-19 pandemic on STEMI patient outcomes have conflicting results. It remains unclear if this may be attributed to regional differences and/or differences during COVID-19 wave periods. Using the American Heart Association Get With The Guidelines–Coronary Artery Disease registry data, we evaluated (1) time metrics related to STEMI system goals and (2) regional variation in STEMI incidence and in-hospital mortality during pandemic wave time periods. The study included all patients 18–100 years old admitted with STEMI (n = 72,516) to 1 of 435 American Heart Association Get With The Guidelines–Coronary Artery Disease hospitals (1 October 2019–31 December 2021). Of these, 70.8% were male and 73.0% non-Hispanic White, with a median age of 63 (IQR 18) years. Compared to pre-pandemic time frames, patients with STEMI had a higher risk profile, delayed time to treatment, were treated with fibrinolytic therapy or primary PCI, and were transferred for primary PCI at similar rates, and had higher adjusted in-hospital mortality (during the second wave in the South and Midwest). Preservation of STEMI systems of care resulted in an overall lower in-hospital mortality rate than predicted, although opportunities exist to improve treatment delays. Regional differences in mortality rates require further study.
Exogenous Hormones, Tumor Intrinsic Subtypes, and Breast Cancer
Cornet, Charlotte Le , Truong, Thérèse, Bolla, Manjeet K. , Koutros, Stella, Stone, Jennifer , Shulman, Katerina, Aronson, Kristan J. , Guénel, Pascal, Patel, Alpa V , Bodelón, Clara , Teras, Lauren R., Shahi, Shamim , Dossus, Laure, Kaaks, R., Holleczek, Bernd , Hoppe, Reiner , Czene, Kamila, Hall, P.F., Mannermaa, Arto, Wu, Anna H. , Obi, Nadia , Panayiotidis, Mihalis I. , Haiman, Christopher A., Shu, Xiao , Perou, Charles M. , Alsten, Sarah Van, Eliassen, A. Heather, Kraft, Peter, Ahearn, Thomas U., Evans, D. Gareth , Wolk, Alicja, Easton, Douglas F., Pharoah, Paul D. P., Vachon, Celine M. , Chang-Claude, Jenny, Evans, D Gareth , Perou, Charles M , Stone, Jennifer , Panayiotidis, Mihalis I , Jung, Audrey , Behrens, Sabine , Middha, Pooja , Truong, Thérèse , Jernström, Helena , Wang, Qin , Southey, Melissa C. , Freeman, Laura E. Beane , Koutros, Stella , Rennert, Gad , Murphy, Rachel A. , Guénel, Pascal , Teras, Lauren R. , Lacey, James V. , Dossus, Laure , Kaaks, Rudolf , Brenner, Hermann , Brauch, Hiltrud , Czene, Kamila, Mannermaa, Arto , Michailidou, Kyriaki , McLean, Catriona , Haiman, Christopher A., Augustinsson, Annelie , Zheng, Wei , Troester, Melissa A. , Abubakar, Mustapha , Ahearn, Thomas U., Wolk, Alicja , Milne, Roger L. , Easton, Douglas F. , Schmidt, Marjanka K. , García‐Closas, Montserrat , Vachon, Celine M. , Fortner, Renée T. , Chang‐Claude, Jenny

Mayo Clinic

JAMA Network Open | July 7, 2025 | Volume: 8 | Issue: 7 | Pages: e2519236

10.1001/jamanetworkopen.2025.19236 | PMID 40622713 Get It

ImportanceEtiologic heterogeneity in breast carcinogenesis needs to be well characterized for targeted prevention. Associations between menopausal hormonal therapy (MHT) and oral contraceptive (OC) use and breast cancer intrinsic-like subtypes are not well understood.ObjectiveTo examine whether exogenous hormone use is differentially associated with breast cancer subtypes and to evaluate heterogeneity by intrinsic-like subtypes.Design, Setting, and ParticipantsThis study pooled data from 31 nested and population-based case-control studies involved in the Breast Cancer Association Consortium. The study population included individuals with breast cancer and control participants from 13 case-control studies nested in prospective cohorts (recruited between 1982 and 2011) and 18 population-based case-control studies (recruited between 1990 and 2013). Data analysis was performed in June 2024.ExposureMHT use (estrogen-progestin therapy [EPT] or estrogen-only therapy [ET]) in postmenopausal women and OC use in premenopausal women (never, past use, or current use).Main Outcomes and MeasuresBreast cancer intrinsic-like subtypes (luminal A–like, luminal B–like, luminal B–ERBB2 [formerly HER2 or HER2/neu]-like, ERBB2 enriched–like, or triple-negative) were determined by immunohistochemistry of tumor sections. Polytomous logistic regression was performed to estimate the association between exogenous hormones and risk of breast cancer by intrinsic-like subtypes. Analyses by subtypes were stratified by body mass index (BMI [calculated as weight in kilograms divided by height in meters squared]; healthy weight, 18.5-&amp;lt;25; overweight, 25-&amp;lt;30; or obesity, ≥30).ResultsThis study included 42 269 individuals with breast cancer (11 901 [28.2%] premenopausal and 30 368 [71.8%] postmenopausal; 23 353 [55.2%] had a known intrinsic-like subtype) and 71 072 control participants. The mean (SD) age of all participants was 57.9 (10.9) years. In postmenopausal women, associations between current MHT use (EPT or ET) and breast cancer differed by subtype. Current EPT users with healthy weight were more likely to be diagnosed with luminal A–like (odds ratio [OR], 2.51 [95% CI, 2.26-2.80]) or luminal B–ERBB2-like (OR, 1.95 [95% CI, 1.61-2.37]) subtypes. These associations were attenuated but remained for individuals with overweight (OR, 1.40 [95% CI, 1.02-1.92]) or obesity (OR, 1.68 [95% CI, 1.01-2.78]). EPT use increased the odds of being diagnosed with luminal B–like tumors solely in women with healthy weight (OR, 1.47 [95% CI, 1.17-1.86]). Current ET use was positively associated with luminal A–like disease in women with healthy weight only (OR, 1.16 [95% CI, 1.01-1.32]), showing inverse associations with higher BMI (obesity: OR, 0.65 [95% CI, 0.50-0.85]). In premenopausal women, recent OC use was associated with luminal B–ERBB2-like (OR, 1.50 [95% CI, 1.09-2.08]), ERBB2 enriched–like (OR, 2.33 [95% CI, 1.55-3.51]), and triple-negative (OR, 1.75 [95% CI, 1.33-2.29]; P &amp;lt; .04 for heterogeneity) tumors.Conclusions and RelevanceIn this study, clear differences were observed in associations between current EPT use and luminal-like breast cancer subtypes and other subtypes. EPT users with healthy weight were more likely to be diagnosed with luminal-like breast cancer compared with nonusers. Subtype heterogeneity was less apparent in associations of OC and ET use. Future studies on contemporary formulations, patterns of use, and routes of administration of exogenous hormone usage are warranted.
The Evaluation of Computer Vision-Based Automated Performance Metrics for Endoscopic Kidney Stone Surgery
Cabo, Jackson , Floyd, Chase, Oğuz, İpek , Kavoussi, Nicholas , Cabo, Jackson , Lu, Daiwei , Koyama, Tatsuki

Mayo Clinic

Journal of Endourology | July 2, 2025 | Volume: 39 | Issue: 9 | Pages: 924-929

10.1089/end.2024.0895 | PMID 40601841 Get It

Background: The assessment of surgical competency is essential for clinical training and safety. No objective, real-time tools exist to evaluate competency during endoscopic stone operation. We sought to apply endoscopic computer vision models to define automated performance metrics (APMs) from videos of flexible ureteroscopy. Materials and Methods: We assessed three APMs for endoscopic treatment of kidney stones, including percentage of frames without stone visibility, screen occupancy by stone, and frame-to-frame change in stone occupancy. Surgical videos of a surgeon performing either stone localization or stone ablation were recorded. Using our previously validated computer vision model for endoscopic stone segmentation, APMs were compared between experts (fellowship-trained endourologists) and trainees. Results: Forty-six videos, including 28 of stone localization and 18 of stone laser ablation, were analyzed from nine surgeons (three experts and six trainees). During stone localization, trainee videos had a higher percentage of frames without visible stone (4% vs 27%, p < 0.01) and lower screen occupancy by stone (5% vs 14%, p = 0.03) compared with expert videos. During laser ablation, trainee videos had a higher frame-to-frame change in stone occupancy (3% vs 2%, p < 0.01) compared with expert videos. Conclusions: APMs from computer vision methods differ between expert and trainee surgical videos of endoscopic kidney stone treatment. These metrics could be used to objectively assess skill evaluation and acquisition.
A Multiomics Study of Circulating Proteins and Kidney Stone Risk
Zhou, Le‐Ting , Stark, Isaac W. , Jayachandran, Muthuvel , Harris, Peter C. , Rule, Andrew D. , Koo, Kevin , Larson, Nicholas B. , Lieske, John C. , Larson, Nicholas B , Lieske, John C , Rule, Andrew D , Harris, Peter C , McDonnell, Shannon K.

Mayo Clinic

Journal of the American Society of Nephrology | June 27, 2025 | Volume: 36 | Issue: 12 | Pages: 2456-2468

10.1681/asn.0000000768 | PMID 40577066 Get It

Key Points Circulating proteins independently associated with kidney stone diagnosis are related to kidney stone matrix. Lower circulating uromodulin and higher scavenger receptor cysteine-rich domain-containing group B protein levels were associated with higher kidney stone risk, whereas kidney stone presence elevates plasma matrix metalloproteinase 7 level. The protective effect of uromodulin against kidney stones was independent of kidney function. Background Kidney stones are increasingly recognized as a systemic disorder with a high global prevalence. However, large proteomics studies are lacking. Methods An individual-level proteomics study with rigorous adjustments was performed on 35,331 UK Biobank participants to uncover the independent associations between 2922 circulating proteins and prevalent kidney stone disease. Mendelian randomization analysis was used to assess causal relationships. Findings were validated using genomic data from the Mayo Clinic Biobank ( N =43,744), concentration-response analysis, transcriptomics analyses, and additional genome-wide association studies. Results Nine plasma proteins were independently associated with a kidney stone diagnosis, including reduced uromodulin (UMOD; β , −0.10; 95% confidence interval [CI], −0.15 to −0.05) and elevated scavenger receptor cysteine-rich domain-containing group B protein (SSC4D; β , 0.28; 95% CI, 0.17 to 0.38) and were enriched in extracellular matrix pathways. Mendelian randomization analysis revealed that the presence of kidney stone contributed to elevated levels of matrix metalloproteinase 7. Conversely, lower plasma UMOD (odds ratio [OR], 0.93; 95% CI, 0.90 to 0.97) and higher plasma SSC4D (OR, 1.10; 95% CI, 1.02 to 1.18) were associated with kidney stone risk. These associations were consistently replicated in the Mayo Clinic Biobank dataset (UMOD; OR, 0.92; 95% CI, 0.86 to 0.98; SSC4D; OR, 1.13; 95% CI, 1.01 to 1.27) and further validated by a concentration-response analysis. Single-nucleus RNA sequencing and quantitative trait loci analyses confirmed consistent associations between thick ascending limb UMOD expression and stone former status and with blood and urine UMOD concentrations. Genome-wide association study analysis, adjusted for eGFR, suggested that the protective role of UMOD against kidney stones was independent of kidney function. Conclusions This study highlights significant associations between concentrations of specific blood proteins and a history of kidney stones. Several implicated proteins are related to kidney stone matrix, with UMOD independently associated with lower risk and SSC4D with higher risk of kidney stones.
Interactions between genetic and epidemiological factors influencing mammographic density
Suger, Austin Hammermeister , Chen, Hongjie , Fan, Shaoqi , Bolla, Manjeet K. , Michailidou, Kyriaki , Wang, Qin , Fasching, Peter A. , Haeberle, Lothar, Aronson, Kristan J. , Eccles, Diana M, Evans, D. Gareth , Astley, Susan , Hall, Per, Pharoah, Paul D P, Antoniou, Antonis C, García‐Closas, Montserrat , González, Amy Berrington de , Easton, Douglas F. , Vachon, Celine M. , Lindström, Sara, Eccles, Diana , Fan, Shaoqi , Bolla, Manjeet K , Dennis, Joe , Michailidou, Kyriaki , Wang, Qin , Stone, Jennifer , Yadav, Siddhartha , Milne, Roger L , Norman, Aaron, Hall, Per N , Czene, Kamila , Pharoah, Paul D P , García-Closas, Montserrat , Easton, Doug , Eccles, Diana , Evans, D Gareth , Berrington de Gonzalez, Amy , Haas, Cameron B. , Scott, Christopher G. , Dunning, Alison M. , Stone, Jennifer , Gago-Domínguez, Manuela , Castelao, Jose E. , Murphy, Rachel A. , Couch, Fergus J. , Yadav, Siddhartha , Milne, Roger L. , Hopper, John L. , Norman, Aaron D. , Eliassen, A. Heather , Tapper, William , Czene, Kamila , Antoniou, Antonis C. , Gierach, Gretchen L. , Tamimi, Rulla M. , Vachon, Celine M. , Harrison, Tabitha A.

Mayo Clinic

American Journal of Epidemiology | March 30, 2025 | Volume: 195 | Issue: 5 | Pages: 1231-1241

10.1093/aje/kwaf067 | PMID 40153356 Get It

Abstract Studies have identified genetic and epidemiologic factors associated with mammographic density (MD) phenotypes. However, MD-associated genetic variants only account for a small proportion of the total estimated heritability. Interrogating interactions between genetic and epidemiologic factors could potentially identify additional MD-associated loci, expand our understanding of the genetic basis of MD phenotypes, and clarify how epidemiologic factors modulate relationships between genetic variants and MD. We conducted six separate genome-wide, gene–environment (GxE) interaction analyses, applying 2 degrees of freedom (df) and 1df interaction tests, for each of three MD phenotypes (percent density, dense area (DA), and nondense area (NDA)). The six epidemiologic factors considered were height, ever parous, parity, ever menopausal hormone therapy, ever breastfeeding, and months of breastfeeding. We included European ancestry participants from multiple studies within the Markers of Density consortium and the Breast Cancer Association Consortium (n = 4895-16 218 depending on specific analyses). We identified 11 loci with genome-wide significant (P &lt; 5 × 10−8) interaction tests including two novel common genetic signals interacting with parity (8p21.2) and ever breastfeeding (19p13.2) for NDA. Our results suggest that epidemiologic risk factors might influence relationships between common genetic variants and MD phenotypes at particular genomic loci.
NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 2.2025
Greenberg, P, Stone, Richard M. , Al‐Kali, Aref , Bennett, John M. , Borate, Uma , Brunner, Andrew M. , Chai‐Ho, Wanxing , Curtin, Peter , Gaensler, Karin, Gahvari, Zhubin, Garcia-Manero, Guillermo, Jacoby, Meagan A., Keel, Sioḃán , Khanal, Rashmi, Maness, Lori J., McMahon, Christine M. , Odenike, Olatoyosi , Osman, Afaf, Sallman, David A. , Sayar, Hamid , Shallis, Rory M. , Tanaka, Tiffany , Kovach, Emily, Nguyen, Jamie , Hochstetler, Cindy, Osman, Afaf E.G. , Osman, Afaf E G , Abaza, Yasmin , Anand, Sarah , Ball, Brian J. , Dezern, Amy Elizabeth , Garcia‐Manero, Guillermo , Griffiths, Elizabeth A. , Haque, Tamanna Zohra , Jonas, Brian A. , Kishtagari, Ashwin , Madanat, Yazan F. , McCurdy, Shannon , Reddy, Vishnu , Singh, Abhay , Thota, Swapna , Kovach, Emily

Mayo Clinic

Journal of the National Comprehensive Cancer Network | March 12, 2025 | Volume: 23 | Issue: 3 | Pages: 66-75

10.6004/jnccn.2025.0013 | PMID 40073835 Get It

The NCCN Guidelines for Myelodysplastic Syndromes (MDS) provide recommendations for the evaluation, diagnosis, and comprehensive care of patients with MDS based on a review of recent clinical evidence that has led to important advances in treatment or has yielded new information on biologic factors that may have prognostic significance in MDS. The multidisciplinary panel of MDS experts is convened at least on an annual basis. During the annual meeting, the panel evaluates new and emerging data to inform their recommendations. These NCCN Guidelines Insights review the recent updates, including treatment recommendations both for lower-risk and higher-risk MDS, preference stratification of therapeutic agents, and emerging data on novel therapeutics.